Literature DB >> 29296954

Related haploidentical donors are a better choice than matched unrelated donors: Point.

Ephraim Joseph Fuchs1.   

Abstract

Publisher's Note: This article has a companion Counterpoint by Shaw. Publisher's Note: Join in the discussion of these articles at Blood Advances Community Conversations.

Year:  2017        PMID： 29296954      PMCID： PMC5738988          DOI： 10.1182/bloodadvances.2016002196

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


  27 in total

1.  Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available.

Authors:  S Garciaz; L Castagna; R Bouabdallah; S Fürst; S Bramanti; D Coso; R Crocchiolo; J El-Cheikh; F Broussais; C Chabannon; A Santoro; D Blaise
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

2.  Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.

Authors:  Shannon R McCurdy; Yvette L Kasamon; Christopher G Kanakry; Javier Bolaños-Meade; Hua-Ling Tsai; Margaret M Showel; Jennifer A Kanakry; Heather J Symons; Ivana Gojo; B Douglas Smith; Maria P Bettinotti; William H Matsui; Amy E Dezern; Carol Ann Huff; Ivan Borrello; Keith W Pratz; Douglas E Gladstone; Lode J Swinnen; Robert A Brodsky; Mark J Levis; Richard F Ambinder; Ephraim J Fuchs; Gary L Rosner; Richard J Jones; Leo Luznik
Journal:  Haematologica       Date:  2016-10-20       Impact factor: 9.941

3.  Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study.

Authors:  Yu Wang; Qi-Fa Liu; Lan-Ping Xu; Kai-Yan Liu; Xiao-Hui Zhang; Xiao Ma; Zhi-Ping Fan; De-Pei Wu; Xiao-Jun Huang
Journal:  Blood       Date:  2015-05-04       Impact factor: 22.113

4.  Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk Index.

Authors:  Asad Bashey; Xu Zhang; Katelin Jackson; Stacey Brown; Michelle Ridgeway; Melhem Solh; Lawrence E Morris; H Kent Holland; Scott R Solomon
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-07       Impact factor: 5.742

5.  Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.

Authors:  Scott R Solomon; Connie A Sizemore; Melissa Sanacore; Xu Zhang; Stacey Brown; H Kent Holland; Lawrence E Morris; Asad Bashey
Journal:  Biol Blood Marrow Transplant       Date:  2015-03-19       Impact factor: 5.742

6.  HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry.

Authors:  Loren Gragert; Mary Eapen; Eric Williams; John Freeman; Stephen Spellman; Robert Baitty; Robert Hartzman; J Douglas Rizzo; Mary Horowitz; Dennis Confer; Martin Maiers
Journal:  N Engl J Med       Date:  2014-07-24       Impact factor: 91.245

7.  Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma.

Authors:  Lauri M Burroughs; Paul V O'Donnell; Brenda M Sandmaier; Barry E Storer; Leo Luznik; Heather J Symons; Richard J Jones; Richard F Ambinder; Michael B Maris; Karl G Blume; Dietger W Niederwieser; Benedetto Bruno; Richard T Maziarz; Michael A Pulsipher; Finn B Petersen; Rainer Storb; Ephraim J Fuchs; David G Maloney
Journal:  Biol Blood Marrow Transplant       Date:  2008-11       Impact factor: 5.742

8.  Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.

Authors:  Anna Maria Raiola; Alida Dominietto; Carmen di Grazia; Teresa Lamparelli; Francesca Gualandi; Adalberto Ibatici; Stefania Bregante; Maria Teresa Van Lint; Riccardo Varaldo; Anna Ghiso; Marco Gobbi; Angelo Michele Carella; Alessio Signori; Federica Galaverna; Andrea Bacigalupo
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-05       Impact factor: 5.742

9.  Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.

Authors:  Abraham S Kanate; Alberto Mussetti; Mohamed A Kharfan-Dabaja; Kwang W Ahn; Alyssa DiGilio; Amer Beitinjaneh; Saurabh Chhabra; Timothy S Fenske; Cesar Freytes; Robert Peter Gale; Siddhartha Ganguly; Mark Hertzberg; Evgeny Klyuchnikov; Hillard M Lazarus; Richard Olsson; Miguel-Angel Perales; Andrew Rezvani; Marcie Riches; Ayman Saad; Shimon Slavin; Sonali M Smith; Anna Sureda; Jean Yared; Stefan Ciurea; Philippe Armand; Rachel Salit; Javier Bolaños-Meade; Mehdi Hamadani
Journal:  Blood       Date:  2015-12-15       Impact factor: 22.113

10.  Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually.

Authors:  J R Passweg; H Baldomero; P Bader; C Bonini; S Cesaro; P Dreger; R F Duarte; C Dufour; J Kuball; D Farge-Bancel; A Gennery; N Kröger; F Lanza; A Nagler; A Sureda; M Mohty
Journal:  Bone Marrow Transplant       Date:  2016-02-22       Impact factor: 5.483
View more
  6 in total

1.  Tandem Orthotopic Living Donor Liver Transplantation Followed by Same Donor Haploidentical Hematopoietic Stem Cell Transplantation for DOCK8 Deficiency.

Authors:  Alexandra F Freeman; Nada Yazigi; Nirali N Shah; David E Kleiner; Mark Parta; Prescott Atkinson; Theo Heller; Steven M Holland; Stuart S Kaufman; Khalid M Khan; Dennis D Hickstein
Journal:  Transplantation       Date:  2019-10       Impact factor: 4.939

2.  A Controlled Trial of Sheng-Yu-Tang for Post-Hematopoietic Stem Cell Transplantation Leukemia Patients: A Proposed Protocol and Insights From a Preliminary Pilot Study.

Authors:  Tom Fleischer; Tung-Ti Chang; Jen-Huai Chiang; Hung-Rong Yen
Journal:  Integr Cancer Ther       Date:  2018-02-11       Impact factor: 3.279

3.  New-onset post-transplant diabetes mellitus after haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide.

Authors:  Brendan L Mangan; Dilan Patel; Heidi Chen; Katie S Gatwood; Michael T Byrne; Salyka Sengsayadeth; Stacey Goodman; Bhagirathbhai Dholaria; Adetola A Kassim; Madan Jagasia; Wichai Chinratanalab; Kathryn A Culos; Brian G Engelhardt
Journal:  EJHaem       Date:  2020-09-23

4.  Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults.

Authors:  Heather J Symons; Marianna Zahurak; Yilin Cao; Allen Chen; Kenneth Cooke; Christopher Gamper; Orly Klein; Nicolas Llosa; Elias T Zambidis; Richard Ambinder; Javier Bolaños-Meade; Ivan Borrello; Robert Brodsky; Amy DeZern; Ivana Gojo; Margaret Showel; Lode Swinnen; B Douglas Smith; Leo Luznik; Richard J Jones; Ephraim J Fuchs
Journal:  Blood Adv       Date:  2020-08-25

5.  ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia.

Authors:  Denis Claude Roy; Irwin Walker; Johan Maertens; Philippe Lewalle; Eduardo Olavarria; Dominik Selleslag; Sylvie Lachance; Marc Buyse; Kun Wang; Jeroen Rovers; Irene Santi; Halvard Bonig; Andrew Sandler; Jurjen Velthuis; Stephan Mielke
Journal:  Leukemia       Date:  2020-02-11       Impact factor: 11.528

6.  Days Alive Outside Hospital and Readmissions in Patients Undergoing Allogeneic Transplants from Identical Siblings or Alternative Donors.

Authors:  Federica Sora; Patrizia Chiusolo; Luca Laurenti; Idanna Innocenti; Francesco Autore; Sabrina Giammarco; Elisabetta Metafuni; Eleonora Alma; Alessia Di Giovanni; Simona Sica; Andrea Bacigalupo
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-09-01       Impact factor: 2.576
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.